Skullcap

Scutellaria lateriflora flavonoids (scutellarin, baicalin) act as GABA-A receptor positive allosteric modulators, producing sedative and anxiolytic effects via the benzodiazepine binding site. This GABAergic mechanism is pharmacologically similar to benzodiazepines. Concurrent use with CNS depressants produces additive CNS depression, excessive sedation, and psychomotor impairment.

Warn patients about additive sedation and impaired psychomotor function. Avoid driving or operating machinery when combining skullcap with CNS depressants. Monitor for excessive sedation and respiratory depression. Reduce doses of sedative medications if combination is necessary.

Skullcap produces CNS depression via GABAergic mechanisms. Additive CNS and respiratory depression can occur when combined with barbiturates. This combination may result in excessive sedation, respiratory compromise, and prolonged sedation requiring medical management.

Monitor for additive CNS and respiratory depression. This combination is clinically relevant when patients use phenobarbital for epilepsy management. Assess need for dose reduction of barbiturate if combination cannot be avoided.

Skullcap flavonoids (scutellarin, baicalin) exhibit anticonvulsant and GABAergic properties that may have additive CNS depressant effects when combined with anticonvulsants. Additionally, in vitro evidence suggests skullcap flavonoids may inhibit CYP2C9 (phenytoin) and CYP1A2, potentially altering plasma levels of certain narrow-therapeutic-index anticonvulsants.

Monitor for excessive sedation and altered anticonvulsant drug levels when combining skullcap with anticonvulsant therapy. Consider monitoring serum phenytoin levels given the potential for CYP2C9 inhibition by flavonoid constituents.

Baicalin and baicalein, the predominant flavonoids in Scutellaria species, inhibit CYP1A2 activity in preclinical and in vitro studies. Scutellaria lateriflora contains structurally similar flavonoids (scutellarin, scutellarein) that share this CYP1A2 inhibitory profile. This may increase plasma concentrations of CYP1A2-metabolized drugs, particularly narrow-therapeutic-index agents.

Monitor for signs of CYP1A2 substrate toxicity (theophylline: tremors, seizures, tachycardia; clozapine: excessive sedation, hypotension) when used with skullcap. Therapeutic drug monitoring for theophylline and clozapine is recommended if combination is used.

Clinical studies with Scutellaria baicalensis extract demonstrated significant inhibition of CYP2C9 activity in human volunteers, as evidenced by reduced metabolic conversion of losartan to its active metabolite (E-3174). Scutellaria lateriflora contains structurally related flavonoids sharing similar CYP2C9 inhibitory potential, potentially increasing plasma levels of warfarin and other CYP2C9 substrates.

Monitor INR closely when skullcap is combined with warfarin. Consider monitoring phenytoin levels. Exercise particular caution in CYP2C9 poor metabolizers. The interaction risk is based on extrapolation from S. baicalensis data — clinical studies with S. lateriflora specifically are needed.

Scutellaria lateriflora has been associated with cases of clinically apparent hepatocellular liver injury, documented in multiple case reports in NIH LiverTox. Cases show hepatocellular enzyme pattern elevation (ALT/AST) within 1-12 weeks of use, with rapid recovery after discontinuation. Co-administration with other hepatotoxic agents increases the risk of drug-induced liver injury (DILI).

Avoid combining skullcap with known hepatotoxic agents. Monitor liver function tests (ALT, AST, bilirubin) in patients using skullcap concurrently with hepatotoxic drugs. Discontinue skullcap immediately if liver enzyme elevations or jaundice occur.

Flavonoids in Scutellaria lateriflora (notably baicalin and wogonin) inhibit binding to serotonin 5-HT7 receptors in vitro, suggesting serotonergic activity beyond simple GABAergic mechanisms. Combined use with SSRIs or SNRIs may produce additive serotonergic-GABAergic effects affecting mood, alertness, and CNS function. Additionally, skullcap inhibits CYP1A2 and CYP2C9 in vitro; some SSRIs/SNRIs rely on these pathways, potentially increasing their plasma levels.

Monitor for excessive sedation, confusion, altered mood, or signs of serotonin excess if skullcap is used alongside SSRIs or SNRIs. Advise patients not to self-medicate anxiety with skullcap while titrating antidepressant doses without medical supervision. Exercise caution with fluvoxamine (CYP1A2 substrate/inhibitor) and warfarin-interacting agents in the context of CYP2C9 overlap.

Scutellaria lateriflora exerts CNS depressant effects via positive allosteric modulation of GABA-A receptors at the benzodiazepine binding site, and demonstrates antispasmodic properties. Co-administration with CNS-active skeletal muscle relaxants—particularly GABAergic baclofen, or centrally-acting cyclobenzaprine and carisoprodol—produces additive CNS depression, increasing risk of excessive sedation, muscle weakness, respiratory depression, and psychomotor impairment. Tizanidine (a CYP1A2 substrate) is of additional pharmacokinetic concern given skullcaps in vitro CYP1A2 inhibitory effects.

Advise patients to avoid using skullcap concurrently with centrally-acting muscle relaxants. If co-use occurs, counsel on avoiding driving or operating heavy machinery. Monitor for excessive sedation and fall risk, particularly in older adults. If tizanidine is being used, be aware of potential CYP1A2-mediated elevation of tizanidine levels (associated with hypotension and sedation).

Skullcap flavonoids act as positive allosteric modulators of GABA-A receptors and exert CNS depressant activity through the benzodiazepine receptor site. Combined with general anesthetics—which cause dose-dependent CNS and respiratory depression—skullcap may potentiate anesthetic depth, prolong recovery time, and increase post-operative sedation. Midazolam, a preoperative BZD commonly used as anxiolytic premedication and also a CYP3A4 substrate, may be additionally affected by skullcaps CYP enzyme interactions.

Patients should discontinue skullcap at least 2 weeks before elective surgery. Anesthesiologists should be informed of skullcap use during preoperative assessment. If accidental perioperative exposure has occurred, increase monitoring of sedation depth and respiratory status in the recovery room. Adjust anesthetic dosing conservatively if recent skullcap use is confirmed.